Success Rate Evaluation of Miniature Pulpotomy With MTA in Primary Molars

NCT ID: NCT02286648

Last Updated: 2014-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the clinical and radiographic success rate of Miniature pulpotomy with Mineral Trioxide Aggregate (MTA) in primary molars.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulpitis Dental Pulp Disease Tooth Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mineral Trioxide Aggregate

pulpotomy with MTA

Group Type EXPERIMENTAL

Mineral Trioxide Aggregate

Intervention Type DRUG

pulpotomy with MTA

Formocresol

pulpotomy with FC

Group Type ACTIVE_COMPARATOR

Formocresol

Intervention Type DRUG

pulpotomy with formocresol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Formocresol

pulpotomy with formocresol

Intervention Type DRUG

Mineral Trioxide Aggregate

pulpotomy with MTA

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy people(without any systemic disease)
* teeth :

* no clinical or radiographic evidence of pulp degeneration
* the possibility of proper restoration of the teeth

Exclusion Criteria

* teeth :

* excessive bleeding from the exposure site
* internal root resorption
* interradicular and/or periapical bone destruction
* swelling or sinus tract
Minimum Eligible Age

4 Years

Maximum Eligible Age

7 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mashhad University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hossein Nematollahi

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mashhad University of Medical Siences

Mashhad, Khorasan Razavi, Iran

Site Status RECRUITING

Mashhad University of Medical Siences

Mashhad, Khorasan Razavi, Iran

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Iran

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hossein Nematollahi, associate prof.

Role: CONTACT

+989151141688

Homa Noorollahian, Associate prof.

Role: CONTACT

+989155577184

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hossein Nematollahi, associate of professor

Role: primary

Homa Noorollahian, associate of professor

Role: backup

Hossein Nematollahi, associate of professor

Role: primary

Homa Noorollahian, associate of professor

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

921762

Identifier Type: -

Identifier Source: org_study_id